RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line

The Wilms' tumor protein 1 (WT1) is essential for tumor cell proliferation and is highly expressed in various hematological and solid malignancies including human malignant melanoma. We investigated whether WT1 expression is essential for growth in the B16F10 murine melanoma cell line. Toward this end, we examined WT1 protein expression and WT1 isoforms (17AA+/17AA−, KTS+/KTS−) in this cell line. WT1 was silenced by two RNA interference constructs, designated WT1-1 and WT1-2. RNA interference-mediated reduction of WT1 protein expression significantly inhibited B16F10 cell viability. Loss of WT1 also increased caspase-3 and poly-ADP-ribose polymerase activation, as well as apoptotic body formation, chromatin condensation, and DNA fragmentation. Together, these findings implicate decreased WT1 protein levels in the induction of apoptosis. These results imply that WT1 plays a distinct role in B16F10 melanoma growth.

[1]  T. Kishida,et al.  Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf , 2007, Gene Therapy.

[2]  Jing Lin,et al.  A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. , 2006, Cancer research.

[3]  D. Becker,et al.  The role of N-Cadherin, MCAM, and β3 integrin in melanoma progression, proliferation, migration and invasion , 2006, Cancer biology & therapy.

[4]  Weida Huang,et al.  Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. , 2006, Biochemical and biophysical research communications.

[5]  Suzie Chen,et al.  From existing therapies to novel targets: a current view on melanoma. , 2006, Frontiers in bioscience : a journal and virtual library.

[6]  B. Perry,et al.  Wilms tumor 1 expression present in most melanomas but nearly absent in nevi. , 2006, Archives of dermatology.

[7]  M. Ruan,et al.  High WT1 Expression Is Associated with Very Poor Survival of Patients with Osteogenic Sarcoma Metastasis , 2006, Clinical Cancer Research.

[8]  S. Kondo,et al.  Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. , 2006, Journal of dermatological science.

[9]  A. Geater,et al.  WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study , 2006, BMC Cancer.

[10]  A. Eggermont.  Randomized trials in melanoma: an update. , 2006, Surgical oncology clinics of North America.

[11]  J. Kirkwood,et al.  Update: current management issues in malignant melanoma. , 2005, Melanoma research.

[12]  J. Tao,et al.  Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach , 2005, The British journal of dermatology.

[13]  W. Hiddemann,et al.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.

[14]  C. Sheehan,et al.  Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship * , 2004, Journal of cutaneous pathology.

[15]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Stigbrand,et al.  Interfering with cancer : a brief outline of advances in RNA interference in oncology , 2004 .

[17]  T. Peretz,et al.  Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. , 2004, Journal of the National Cancer Institute.

[18]  K. Wagner,et al.  The complex life of WT1 , 2003, Journal of Cell Science.

[19]  L. Ellisen.  Regulation of Gene Expression by WT1 in Development and Tumorigenesis , 2002, International journal of hematology.

[20]  Musaffe Tuna,et al.  Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. , 2002, Biochemical and biophysical research communications.

[21]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[22]  X. Tian,et al.  WT1 downregulation during K562 cell differentiation and apoptosis induced by bufalin. , 2002, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[23]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Goldstein,et al.  Diagnosis and management of malignant melanoma. , 2001, American family physician.

[25]  E. Bertelmann,et al.  Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens , 2000, Journal of Cancer Research and Clinical Oncology.

[26]  X. Wu,et al.  [Effect of WT1 antisense oligonucleotide on proliferation and apoptosis of human leukemia cells]. , 1999, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[27]  D. Lubahn,et al.  Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas , 1999, Breast Cancer Research and Treatment.

[28]  A. Albino,et al.  Update of diagnostic and prognostic markers in cutaneous malignant melanoma. , 1999, Dermatologic clinics.

[29]  Brown Tj,et al.  Malignant melanoma: a clinical review. , 1999 .

[30]  Y. Oji,et al.  Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth , 1999, Japanese journal of cancer research : Gann.

[31]  A. Shilkaitis,et al.  Molecular prognostic markers in intermediate‐thickness cutaneous malignant melanoma , 1999, Cancer.

[32]  C. A. Kuhn,et al.  Current Status of Melanoma Vaccines , 1997, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[33]  A. Kopf,et al.  The incidence of malignant melanoma in the United States: issues as we approach the 21st century. , 1996, Journal of the American Academy of Dermatology.

[34]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[35]  P. Smith,et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.

[36]  D. Morton,et al.  The role of adjuvant therapy in melanoma management , 1995, Cancer.

[37]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[38]  E. Thiel,et al.  Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes , 1994, International journal of cancer.

[39]  J. M. Mcgee.  Immunotherapy for malignant melanoma: a review and update. , 1991, Seminars in surgical oncology.

[40]  R. Baggs,et al.  A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.

[41]  B. Thiers.  Immunotherapy of malignant melanoma. , 1982, Journal of the American Academy of Dermatology.

[42]  L. Klein-Hitpass,et al.  WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. , 2005, Haematologica.

[43]  C. Densmore,et al.  Aerosol delivery of PEI–p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis , 2002, Cancer Gene Therapy.

[44]  B. Nelson,et al.  Malignant melanoma: a clinical review. , 1999, Cutis.

[45]  P. Elvin,et al.  Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system. , 1984, European journal of cancer & clinical oncology.